with various cancer therapies, including aromatase inhibitor (AI) therapy in postmenopausal women and AI therapy and gonadotropin-releasing hormone (GnRH) agonists in pre-menopausal women with breast cancer, bone marrow transplantation in patients with
Search Results
Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster
proven to be 76% as effective as tamoxifen in reducing the overall risk of invasive breast cancer (RR, 1.24; 95% CI, 1.05–1.47). 6 Two aromatase inhibitors have been investigated for the primary prevention of breast cancer. MAP.3 was a randomized
D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff
2006 ; 11 : 704 – 717 . 42 Miller WR Bartlett J Brodie AM . Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008 ; 13 : 829 – 837 . 43 Normanno
Adam L. Cohen and John H. Ward
with breast cancer stop taking it early. 15 – 17 Therefore, an individualized approach to balancing the benefits and risks of tamoxifen is appropriate. Risk Reduction With Other Drugs Both aromatase inhibitors and human epidermal growth factor
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
significantly improve PFS compared with hormone therapy alone in patients with advanced HR+/HER2– breast cancer, 6 , 7 leading to FDA approval of palbociclib in combination with an aromatase inhibitor (AI; as first-line therapy) in February 2015, and with
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
6 months after treatment. Median and mean time taking opioids was 0.7 and 1.9 weeks, respectively. New opioid users were more likely to receive multimodality treatment and aromatase inhibitors, and persistent opioid users were more likely to receive
Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor, and Courtney Vito
/radiation, or mastectomy. 1 When breast conservation is used, the risk of local recurrence is higher than with mastectomy. 1 Antiestrogen (anti-e) therapy, in the form of either tamoxifen or an aromatase inhibitor (AI), may be used to reduce the risk of local
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
postmenopausal women, except that tamoxifen is the preferred adjuvant treatment. 5 – 9 There are limited clinical data on the efficacy of single-agent aromatase inhibitors in men, and aromatase inhibitors may be combined with gonadotropic hormone
Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith
-up of the effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole . Presented at the 2006 San Antonio Breast Cancer Symposium ; December 14–17, 2006 ; San
Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov
. 10.1016/S1470-2045(09)70314-6 20005174 2. Dowsett M , Cuzick J , Ingle J , . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen . J Clin Oncol 2010 ; 28 : 509 – 518 . 19949017 10.1200/JCO
